A Long-Term Extension Study to Evaluate Safety and Efficacy of Verekitug (UPB-101) in Adult Participants With Severe Asthma Who Completed the VALIANT Trial
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Verekitug (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms VALOUR
- Sponsors Upstream Biosciences
Most Recent Events
- 11 Jun 2025 Status changed from not yet recruiting to recruiting.
- 12 May 2025 New trial record
- 11 May 2025 Status changed from planning to not yet recruiting.